ArticleHeliyon2024
Development of peptone-based serum-free media to support Vero CCL-81 cell proliferation and optimize SARS-CoV2 viral production.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fetal bovine serum: how to leave it behind in the pursuit of more reliable science.Frontiers in toxicology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Developing an optimal media for Vero cell lines is crucial as it directly influences cell survival, proliferation, and virus production. The use of serum in cell culture raises safety concerns in biological production. The United States Food and Drug Administration (FDA) and the European Medicines Agency have implemented stricter regulations on the use of animal-derived components in commercial protein manufacturing to ensure patient safety. Objective: This study aims to develop new chemically defined media using peptone hydrolysate as a serum-free alternative. Methods: A rational experimental design was employed to screen and optimize potential serum substitutes. Six types of peptones were tested at varying concentrations to determine the top three candidates. These candidates were subsequently combined into five mixtures to identify the two most effective serum-free media for Vero CCL-81 cells. The evaluation criteria included morphology observation and proliferation assay. The two most promising serum-free formulations were further evaluated for their ability to support virus production and using TCID Results: The results of this study indicate that Mixture 4, consisting of 0.5 g/L Phytone™ Peptone, 0.5 g/L Difco™ Soytone, and 2 g/L Bacto™ Malt, significantly enhanced Vero CCL-81 cell proliferation and produced high viral titers. The developed medium demonstrated comparable performance to commercially available serum-free media. Conclusion: Peptone-based serum-free media provide a robust alternative for supporting Vero CCL-81 cell growth and are suitable for virus production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.